Investigational drug · Phase 2
REGN5459
Also called: Vonsetamig, BCMAxCD3
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Kidney Disease (CKD), Relapsed Multiple Myeloma, Refractory Multiple Myeloma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "REGN5459"
First trial start
2019
Sep 26, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN5459", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Kidney Disease (CKD)
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Chronic kidney disease · Hematology and blood cancers · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN5459" as an intervention, largest first.
- Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus NephritisRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06975787 · 90 participants (planned) · Start Dec 22, 2025 · Primary completion Sep 10, 2029
Drug: Vonsetamig; Odronextamab · For: Lupus Nephritis (LN)
Sites: San Francisco, California; Gainesville, Florida; Rochester, Minnesota · 20 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04083534 · 43 participants · Start Sep 26, 2019 · Primary completion May 1, 2025
Drug: REGN5459 · For: Relapsed Multiple Myeloma; Refractory Multiple Myeloma
Sites: Indianapolis, Indiana; Ann Arbor, Michigan; Rochester, Minnesota · 7 sites in all
- A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)Active, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05092347 · 43 participants · Start Aug 2, 2022 · Primary completion Nov 22, 2027
Drug: Vonsetamig · For: Chronic Kidney Disease (CKD)
Sites: Los Angeles, California; Orange, California; San Francisco, California · 10 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05106387 · 20 participants (planned) · Start Oct 19, 2023 · Primary completion Jun 14, 2027
Drug: Noninterventional · For: Chronic Kidney Disease (CKD)
Sites: Los Angeles, California; Orange, California; San Francisco, California · 9 sites in all
- Compassionate Use of VonsetamigAvailable
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07780110
Drug: Vonsetamig · For: Plasma Cell Mediated; Antibody Mediated
Newest research
PubMed records naming it or its code names, newest first.
- A small proportion of CD8 T cells expand robustly when stimulated with BCMAxCD3 bispecific T-cell engagers in vitro.
Shibata K, Tsutsumi K, Murakami H, et al. · Leukemia 2026
- Efficient Generation of Functional TCRαβ+ Cytotoxic T Cells from hiPSCs via Small-Molecule Modulation.
Kubaczka C, Kambli N, Windisch R, et al. · bioRxiv 2026
- Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen.
Lowy JA, Rogers MF, Avigan ZM, et al. · Expert Rev Hematol 2026
- Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.
Cani L, Scott SA, Roberts D, et al. · Haematologica 2026
- An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma.
Costa LJ, LeBlanc TW, Tesch H, et al. · Blood Lymphat Cancer 2025
- Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.
Varma G, Fogel L, Gordon B, et al. · Leuk Lymphoma 2025
Also in development for Chronic Kidney Disease (CKD)
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- PLS240upacicalcetPhase 33 trials
Pathalys Pharma · Secondary Hyperparathyroidism, Chronic Kidney Disease (CKD), End-stage Kidney Disease (ESKD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.